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Pulmonary artery banding in Eisenmenger
complex
To the Editor:
The news article titled “Batista Strikes Again to Tackle
Eisenmenger Complex,” published in the May 1997 issue
of The Lancet, has prompted us to review the strategies for
surgical management of patients with Eisenmenger syn-
drome. As a primary step in the treatment of patients with
Eisenmenger complex, Batista1 proposes pulmonary ar-
tery (PA) banding to dilate the pulmonary vascular bed by
reducing PA oxygen saturation (Sao2). Later, when PA
and systemic pressures and arterial blood Sao2 return to
normal values, debanding of the PA and correction of
congenital heart defects are indicated.1 This news brings
to mind an article by Wagenvoort, Wagenvoort, and
Draulans-Noe¨,2 in which the authors compared the mor-
phologic changes in lung biopsy specimens of patients
with congenital heart disease with a shunt and pulmonary
hypertension before and after banding of the PA. These
investigators reported that medial hypertrophy regressed
after PA banding, and in plexogenic pulmonary arteriopa-
thy, the earlier lesions, particularly cellular intimal prolif-
eration, also regressed.
Although lung and heart-lung transplantation are the
only definitive treatments for most adults with Eisen-
menger syndrome, Hopkins and associates3, 4 report that
the natural survival of these patients is better than survival
achieved with transplantation. In this regard, they have
tried to identify means other than transplantation to
improve their quality of life.
Because increased flow is an important pathogenic
element in producing pulmonary hypertension, Dammann
and colleagues5 first performed PA banding to reduce
pulmonary blood flow and PA hypertension and thereby
therapeutically improve congestive heart failure. Serial
biopsy specimens provided good evidence that PA band-
ing was following by regression of the hypertensive
changes in the lung vasculature.5 Batista and associates1
postulate that high PA Sao2, rather than hyperflow, is the
main cause of PA vasoconstriction and PA vascular
resistance. A review6 of the experimental data concerning
the effect of hypoxia on the pulmonary circulation does
not support that hypothesis. Interestingly, in isolated pig
lungs, Sylvester and associates7 observed that reduction of
the alveolar oxygen tension to a level of 50 to 30 mm Hg
led to hypoxic pulmonary vasodilation.
Goldblatt and coworkers8 presume that, in the presence
of a right-to-left shunt, PA banding would increase cardiac
embarrassment, both physiologically and hemodynami-
cally. With a right-to-left shunt, the PA pressure is still
increased, but the pulmonary blood flow is not.8 It is
important to decide how much the PA pressure can be
reduced without compromising the heart’s ability to per-
fuse a highly resistant pulmonary arteriolar bed in Eisen-
menger complex.8 In the course of PA banding, systemic
Sao2 was reduced from 97% to 60% or 75% and pulmo-
nary Sao2 from 87% to about 20%
1 in patients with
right-to-left shunt without compromising the heart (no
respiratory acidosis developed, per a personal communi-
cation with Dr. Randas Batista).
Brammell and colleagues9 suggest that if the pulmonary
vascular bed is reactive, PA banding is not contraindicated
in Wood’s definition of Eisenmenger syndrome. To avoid
a catastrophic outcome, before operating, one can evalu-
ate the reactivity of the pulmonary vascular bed to PA
banding by partially occluding the PA with a balloon-
tipped catheter during preoperative catheterization.
What options remain when lung or heart-lung trans-
plantation is not possible or even advisable,3, 4 especially
for patients from a poor socioeconomic condition who
have pulmonary vasculature changes of Heath-Edwards
grade IV-VI? The choices may be PA banding, with all
supportive measures, or death.
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Outcome of atrial fibrillation after mitral valve
repair
To the Editor:
The article by Obadia and associates1 in the August
1997 issue of this Journal evaluates some of the factors
that influence the return to sinus rhythm (SR) from
preoperative atrial fibrillation (AF) after mitral valve
repair. I shall only be referring to those patients whom the
authors have called the permanent fibrillation group
(about 70% of their patients with AF). Duration of AF
was the most important factor identified, being more
predictive than left atrial diameter. Although this is widely
acknowledged to be the case, another prognostic factor
that helps to identify patients whose rhythm is likely to
revert to SR, and possibly continue in SR in the late
postoperative period, is the outcome of primary cardio-
version intraoperatively.
I would like to share our experience with patients in AF
undergoing mitral valve replacement (MVR), which we
published some years back2 and believe is equally perti-
nent in mitral valve repair.
In all patients with AF who were undergoing MVR, we
tried intraoperative direct-current cardioversion (primary
cardioversion) soon after separation from cardiopulmo-
nary bypass. Synchronized shocks of 10 to 50 joules were
delivered to the heart, and attempts were made to capture
the SR, if present, on biatrial pacing. Pacing was contin-
ued for 48 to 72 hours after the operation if this primary
cardioversion was successful. Logically, such patients
(group A) would be in a superior hemodynamic state
in the critical postoperative period in the intensive care
unit than those whose rhythm did not convert to SR
(group B). All discharged patients of group B, and those
of group A whose rhythm reverted to AF after only a few
days of SR, were called back for a secondary cardioversion
after varying intervals in the postoperative follow-up. We
studied 75 such patients prospectively over a 4-year pe-
riod.
We observed that the results of secondary cardioversion
were much better in group A patients (80.9% immediate
conversion to SR) than in group B (36.4% conversion to
SR). Also, at the end of 1 year, 55.5% of group A patients
and only 19.3% in group B were still in SR. The most
likely candidate for a successful cardioversion in our study
was a patient with a duration of AF less than 2 years and
in whom it was possible to convert to SR at the time of the
operation. On the basis of these conclusions, we recom-
mended that all patients in AF undergoing MVR should
have an electric cardioversion during the operation. If
successful, SR should be maintained by atrial pacing for
48 to 72 hours for a smoother immediate postoperative
recovery. When discharged patients in AF are called in for
a secondary cardioversion, success is more likely if the
response to primary cardioversion was positive, even if the
SR did not last long.
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Single or bilateral lung transplantation for
chronic obstructive pulmonary disease
To the Editor:
We read with interest the article by Bavaria and col-
leagues1 concerning bilateral (BLT) versus single (SLT)
lung transplantation for chronic obstructive pulmonary
disease (COPD) and would like to make the following
comments:
The primary indication for transplantation in COPD is
to relieve the patient’s symptoms, not to improve longev-
ity. It is therefore difficult to justify the use of a pair of
lungs in patients with COPD when there is an ever-
increasing and obligatory need for BLT in patients with
cystic fibrosis.
We believe it is difficult to draw any comparison,
because the groups differed demographically.
The mean ages of the two groups differed substantially,
the BLT recipients being significantly younger (48.8 vs
55.3 years, p , 0.001). More than half of the BLT
recipients were men, compared with less than a third of
the SLT recipients (58.6% vs 27.7%: p 5 0.007). There is
sufficient data to show that patients less than 50 years of
age have a significantly improved life expectancy and that
being male gives one a better chance of survival than
being female.2 Finally, we were surprised that the authors
could “favorably compare” their 28.3% 1-year mortality
for the SLT recipients to the Washington University figure
of 10.3%.3 Indeed, survival figures from the Heart and
Lung Transplant Registry indicate 1-year mortality for
SLT and BLT to be 19.81% and 17.96%, respectively (p .
0.05).2
Although we entirely agree that BLT would result in
better pulmonary function, quality of life, and life expect-
ancy, it is hard to justify the practice of BLT in patients
with COPD, and confusion may occur when such figures
are quoted without comparing two demographically sim-
ilar groups.
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